Balanced news tone
News Sentiment
MDGL sentiment intelligence
Madrigal Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+3.1% over one week, +9.4% over four weeks, trend active, and materially above fair value.
Dow, S&P 500, Nasdaq Futures Rise After Trump’s 10-Day Iran Pause: Why META, DJT, U, KOD, MDGL Are Trending After-Hours
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Madrigal (MDGL) Baker Bros.-aligned directors receive RSU and option awards
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 Jun 2026 07:00
- Source
- Market source
Madrigal Pharmaceuticals (MDGL) slides as insider sale headlines hit and investors take profits
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Quiver Quantitative
Madrigal Pharmaceuticals Could Become The Next Vertex
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Seeking Alpha
Madrigal (MDGL) CMO sells 1,042 shares in 10b5-1 trade, holds 10,033
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Stock Titan
MDGL (NASDAQ) insider files Form 144 reporting sale of 1,042 shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Stock Titan
Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 May 2026 07:00
- Source
- simplywall.st
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales Growth
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 10 May 2026 07:00
- Source
- Market source
Madrigal Pharmaceuticals (MDGL) Quarterly Loss Of US$94 Million Tests Bullish Margin Turnaround Narrative
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- simplywall.st
Madrigal Expands MASH Franchise With Precision RNAi License For ARO PNPLA3
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 06 May 2026 07:00
- Source
- simplywall.st
Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- Market source
Is It Time To Reassess Madrigal Pharmaceuticals (MDGL) After Its Strong Five Year Share Price Gain
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 03 May 2026 07:00
- Source
- simplywall.st
Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 29 Apr 2026 07:00
- Source
- Market source
Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish (NASDAQ:MDGL)
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 28 Apr 2026 07:00
- Source
- Seeking Alpha
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 27 Mar 2026 07:00
- Source
- Market source
Is Madrigal Pharmaceuticals (MDGL) Pricing Look Interesting After Long Term Share Price Surge?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 11 Mar 2026 07:00
- Source
- Market source
What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Mar 2026 07:00
- Source
- Market source
Madrigal learns its MASH drug Rezdiffra must share U.S. market, then gets Europe all to itself
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Aug 2025 07:00
- Source
- The Business Journals
Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 13 Aug 2025 07:00
- Source
- simplywall.st